Amprion Advances Early Detection for Parkinson’s and Alzheimer’s | Propel(x)

Amprion, a Propel(x) portfolio company, is transforming how Parkinson’s disease, Alzheimer’s disease, and related neurodegenerative disorders are detected. The company continues to gain momentum with meaningful clinical, regulatory, and commercial progress.

Recent Progress from Amprion

• Expanded access to diagnostic testing
  A new partnership with Mayo Clinic Laboratories allows Amprion’s test to reach more patients and healthcare providers across the United States.
• Faster and more comprehensive results
  Updated biomarker panels now analyze multiple biological signals rather than a single marker, giving clinicians clearer insight into brain pathology.
• Growing FDA support
  The FDA issued a Letter of Support recommending Amprion’s technology for use in clinical trials, reinforcing its value for early disease detection.
• International expansion and new patents
  Newly granted patents in Europe and the UK position Amprion to expand its diagnostic platform into global markets.
• Strong validation and investor confidence
  New funding, industry recognition, and autopsy-confirmed accuracy data continue to validate the reliability and clinical relevance of the technology.

Amprion’s progress highlights how science-driven companies in the Propel(x) portfolio are shaping the future of early, biology-based diagnostics for neurodegenerative disease.

Register on Propel(x) to explore alternative investment opportunities:
https://www.propelx.com/